Importantly, different cancer types, such as acute and chronic myeloid leukemia (AML and CML) [14, 15], multiple myeloma [16], melanoma [17], K-Ras–driven pancreatic cancer [18], PTEN-mutated breast cancer or glioblastoma [19], and chemotherapy-resistant triple-negative breast cancer cells [13], have been found to be vulnerable to the inhibition of DHODH. The gene discussed is KRAS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.